Related Experiment Video
Updated: Jul 15, 2026
06:56
Development and Application of Rapamycin-regulated Tyrosine Phosphatases
Published on: September 6, 2024
How to control lymphangiogenesis: a novel role for rapamycin
1Department of Pathology, Medical University of Vienna-Allgemeines Krankenhaus, Vienna, Austria. dontscho.kerjaschki@meduniwien.ac.at
Kidney International
|April 13, 2007
Summary
Rapamycin effectively inhibits lymphangiogenesis, the formation of new lymphatic vessels. This finding is crucial for understanding and potentially treating conditions like renal transplant rejection.
Area of Science:
- Vascular Biology
- Immunology
- Pharmacology
Background:
- Recent discoveries of specific lymphatic endothelial cell markers enable lymphatic microvasculature analysis.
- Therapeutic targeting of lymphangiogenesis holds potential for clinical applications, including managing renal transplant rejection.
Discussion:
- Huber et al. investigate the effects of rapamycin on lymphangiogenesis.
- The study focuses on the role of rapamycin in inhibiting the formation of new lymphatic vessels.
Key Insights:
- Rapamycin demonstrates significant efficacy as an inhibitor of lymphangiogenesis.
- This inhibition mechanism could be a novel therapeutic strategy.
Outlook:
- Further research may explore rapamycin's clinical utility in preventing or treating diseases involving aberrant lymphangiogenesis.
- Understanding rapamycin's impact on lymphatic vessel formation could advance treatments for transplant rejection and other immune-related disorders.
Related Concept Videos
03:03mTOR Signaling and Cancer Progression
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
01:22PI3K/mTOR/AKT Signaling Pathway
The mammalian target of rapamycin (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast, mTORC2 consists of a rapamycin-insensitive companion...
01:24Regulation of Angiogenesis and Blood Supply
Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits. Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl hydroxylase and factor...
02:23Abnormal Proliferation
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the daughter...
01:20The JAK-STAT Signaling Pathway
Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as SH2...
01:10Mechanism of Angiogenesis
Blood vessel formation starts early during embryonic development, around day 7. In the extraembryonic yolk sac, mesodermal precursor cells called hemangioblast proliferate and differentiate into angioblast. Angioblasts express vascular endothelial growth factor receptor 2 or VEGFR2, which binds VEGF-A, a proangiogenic factor, guiding blood vessel formation. VEGF signaling promotes angioblasts to form a blood island in the developing embryo. Angioblasts further differentiate, giving rise to...